Abbott Laboratories (ABT) Q4 FY2025 earnings: revenue $11.5 billion, up 4.4% on the year

Abbott Laboratories (ABT) reported revenue of $11.5 billion for Q4 FY2025, the quarter ended 31 December 2025, up 4.4% on the same quarter a year earlier. Net income was $1.8 billion, down 80.8% on the year, and diluted earnings per share $1.01. The figures are the company's own, from the 10-K it filed with the SEC on 20 February 2026.

Revenue

$11.5 billion

+4.4% on the year · +0.8% on the quarter

Q1 FY2024Q4 FY2025

Operating margin

19.6%

17.4% a year earlier

Q1 FY2024Q4 FY2025

Net income

$1.8 billion

-80.8% on the year · +8.0% on the quarter

Q1 FY2024Q4 FY2025

Diluted EPS

$1.01

-80.8% on the year · +7.4% on the quarter

Q1 FY2024Q4 FY2025

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 3 new.

Fourth-quarter sales grew 4.4 percent: Sales were $11.459 billion, up 4.4 percent reported and 3.0 percent organic. Excluding COVID-19 testing-related sales, organic growth was 3.8 percent.
Quarterly adjusted EPS grew 12 percent: GAAP diluted EPS was $1.01 and adjusted diluted EPS was $1.50. Specified items reduced GAAP diluted EPS by $0.49 in the quarter.
Full-year sales reached $44.3 billion: Full-year 2025 sales rose 5.7 percent reported and 5.5 percent organic. Excluding COVID-19 testing-related sales, organic growth was 6.7 percent.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q4 FY2025	Q3 FY2025	Q4 FY2024	On the quarter	On the year
Revenue	11,459	11,369	10,974	+0.8%	+4.4%
Cost of revenue	4,922	5,075	4,942	-3.0%	-0.4%
Gross profit	6,537	6,294	6,032	+3.9%	+8.4%
Gross margin	57.0%	55.4%	55.0%
Research and development	735	766	749	-4.0%	-1.9%
Selling, general and administrative	3,129	3,051	2,907	+2.6%	+7.6%
Operating income	2,251	2,057	1,911	+9.4%	+17.8%
Operating margin	19.6%	18.1%	17.4%
Interest expense	120	121	136	-0.8%	-11.8%
Pre-tax income	2,358	2,180	2,030	+8.2%	+16.2%
Income tax	582	536	-7,199	+8.6%
Effective tax rate	24.7%	24.6%	-354.6%
Net income	1,776	1,644	9,229	+8.0%	-80.8%
Net margin	15.5%	14.5%	84.1%
Diluted EPS	$1.01	$0.94	$5.27	+7.4%	-80.8%

$ million except per share.

Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q4 FY2025	Q3 FY2025	Q4 FY2024	On the quarter	On the year
Operating cash flow	3,315	2,787	2,868	+18.9%	+15.6%
Capital expenditure	689	496	720	+38.9%	-4.3%
Free cash flow	2,626	2,291	2,148	+14.6%	+22.3%
Free cash flow margin	22.9%	20.2%	19.6%
Cash from investing	-913	-457	-866
Cash from financing	-1,397	-1,760	-1,861
Depreciation and amortisation	792	791	807	+0.1%	-1.9%
Share-based compensation	113	120	111	-5.8%	+1.8%
Buybacks	302	305	315	-1.0%	-4.1%
Dividends paid	1,030	1,031	958	-0.1%	+7.5%
Dividend per share	n/a	$0.59	n/a
Diluted shares, weighted	1,748m	1,749m	1,748m	-0.1%	0.0%
Shares outstanding at period end	1,738m	1,739m	1,734m	-0.1%	+0.2%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q4 FY2025	Q3 FY2025	Q4 FY2024	On the quarter	On the year
Shareholders' equity	52,130	50,954	47,664	+2.3%	+9.4%
Non-controlling interest	641	310	237	+106.8%	+170.5%
Debt	12,929	12,941	14,125	-0.1%	-8.5%
Operating lease liabilities	931	n/a	896		+3.9%
Other liabilities	20,082	19,976	18,492	+0.5%	+8.6%
Total liabilities and equity	86,713	84,181	81,414	+3.0%	+6.5%
Fixed assets	11,816	11,504	10,658	+2.7%	+10.9%
Goodwill	24,035	23,971	23,108	+0.3%	+4.0%
Intangible assets	5,526	5,598	6,647	-1.3%	-16.9%
Investments	1,335	1,173	1,237	+13.8%	+7.9%
Cash and equivalents	8,522	7,511	7,616	+13.5%	+11.9%
Receivables	7,929	8,138	6,925	-2.6%	+14.5%
Inventory	6,488	6,708	6,194	-3.3%	+4.7%
Other assets	21,062	19,578	19,029	+7.6%	+10.7%
Total assets	86,713	84,181	81,414	+3.0%	+6.5%

Questions

What was Abbott Laboratories' revenue in Q4 FY2025?

Abbott Laboratories (ABT) reported revenue of $11.5 billion for Q4 FY2025, the quarter ended 31 December 2025, up 4.4% on the same quarter a year earlier.

How much did Abbott Laboratories earn in Q4 FY2025?

Net income for Q4 FY2025 was $1.8 billion, down 80.8% on the year, and diluted earnings per share $1.01.

When did Abbott Laboratories report Q4 FY2025 results?

Abbott Laboratories filed its 10-K for the year that ended with the quarter on 20 February 2026; the fourth quarter is the year less the first three.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	11,468	11,895	11,257	10,410	10,091	9,747	9,978	10,143	10,241	9,964	10,377	10,635	10,974	10,358	11,142	11,369	11,459	11,164	12,593	13,013
Cost of revenue	4,766	4,987	4,933	4,629	4,593	4,331	4,483	4,605	4,556	4,463	4,603	4,698	4,942	4,468	4,854	5,075	4,922	4,890	5,325	5,628
Gross profit	6,702	6,908	6,324	5,781	5,498	5,416	5,495	5,538	5,685	5,501	5,774	5,937	6,032	5,890	6,288	6,294	6,537	6,274	7,268	7,385
Gross margin	58%	58%	56%	56%	54%	56%	55%	55%	56%	55%	56%	56%	55%	57%	56%	55%	57%	56%	58%	57%
R&D	762	697	684	782	725	654	715	672	700	684	698	713	749	716	725	766	735	767	892	920
SG&A	3,048	2,787	2,757	2,731	2,973	2,762	2,740	2,723	2,724	2,959	2,936	2,895	2,907	3,061	3,091	3,051	3,129	3,740	4,025	4,266
Operating income	2,378	2,912	2,376	1,770	1,304	1,509	1,542	1,647	1,780	1,386	1,669	1,859	1,911	1,693	2,052	2,057	2,251	1,345	1,693	1,358
Operating margin	21%	24%	21%	17%	13%	15%	15%	16%	17%	14%	16%	17%	17%	16%	18%	18%	20%	12%	13%	10%
Interest expense	131	131	132	141	154	153	159	166	159	141	140	142	136	131	121	121	120	174	351	350
Pre-tax income	2,327	2,876	2,352	1,758	1,320	1,562	1,636	1,671	1,795	1,436	1,607	1,940	2,030	1,778	2,150	2,180	2,358	1,449	1,524	1,231
Tax rate	15%	15%	14%	18%	22%	16%	16%	14%	11%	15%	19%	15%	-355%	25%	17%	25%	25%	26%	39%	25%
Net income	1,989	2,447	2,018	1,435	1,033	1,318	1,375	1,436	1,594	1,225	1,302	1,646	9,229	1,325	1,779	1,644	1,776	1,077	928	920
Net margin	17%	21%	18%	14%	10%	14%	14%	14%	16%	12%	13%	15%	84%	13%	16%	14%	15%	10%	7%	7%
Diluted EPS	$1.11	$1.37	$1.14	$0.81	$0.59	$0.75	$0.78	$0.82	$0.91	$0.70	$0.74	$0.94	$5.27	$0.76	$1.01	$0.94	$1.01	$0.61	$0.53	$0.53
Operating cash flow	3,067	2,065	2,410	2,780	2,326	1,143	1,203	1,877	3,038	1,025	1,960	2,705	2,868	1,417	2,047	2,787	3,315	1,315	2,488	1,737
Capital expenditure	614	321	379	467	610	380	507	560	755	398	533	556	720	484	502	496	689	399	497	513
Free cash flow	2,453	1,744	2,031	2,313	1,716	763	696	1,317	2,283	627	1,427	2,149	2,148	933	1,545	2,291	2,626	916	1,991	1,224
Buybacks	974	2,307	5.0	798	685	540	426	2.0	259	226	3.0	751	315	280	6.0	305	302	180	1,045	11.0
Dividends paid	798	832	828	826	823	890	890	888	888	957	961	960	958	1,026	1,029	1,031	1,030	1,098	1,102	1,094
Shares outstanding	1,763m	1,751m	1,751m	1,744m	1,738m	1,739m	1,735m	1,736m	1,735m	1,740m	1,740m	1,734m	1,734m	1,740m	1,740m	1,739m	1,738m	1,742m	1,730m	1,732m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2025, filed 20 February 2026: the filing.